Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CC-EIEs in Cervical Cancer
NCT03362619Phase 2Terminated
- Sponsor
- Shenzhen Geno-Immune Medical Institute
- Start
- Jun 2026
- Primary completion
- Jul 2026
- Modality
- Allogeneic CAR-T, Tumor-Infiltrating Lymphocytes (TILs), TCR-Engineered T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of CC-EIEs in Cervical Cancer (CC), sponsored by Shenzhen Geno-Immune Medical Institute. Primary endpoint: Safety of CC-EIEs (CTCAE v4.0) at 6 months. Started Jun 2026; status: terminated.
02
Drugs
CC-EIEs
03
Conditions
Cervical Cancer (CC)
Beyond the preview
Go deeper on NCT03362619.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03362619.